Clinical Perspective on Exophiala dermatitidis, A Systematic Review of Cases Reported Globally over 36 Years.

MycopathologiaSep 16, 2026 (epub)

Tianyang Chen, Mingyuan Han, Ying Miao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 77 reported cases of Exophiala dermatitidis infections from 1989 to 2024, highlighting a rise in cases, particularly since 2010. The study found that 54.55% of infections occurred in immunocompromised individuals, with deep-seated infections being most prevalent (76.62%). The mortality rate was notably high for central nervous system infections (63.63%).

Key findings

  • 64.9% of cases were reported since 2010, indicating increased awareness.
  • 54.55% of infections occurred in immunocompromised hosts.
  • 76.62% of infections were deep-seated.
  • 63.63% mortality rate for central nervous system infections.

Why it matters

Understanding the epidemiology and risk factors associated with Exophiala dermatitidis is crucial for clinicians, as it highlights the need for vigilance in diagnosing and managing infections, particularly in immunocompromised patients.

Source

Published in Mycopathologia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.